Efficacy of probiotics combined with omeprazole in the treatment of acute gastroenteritis in children
10.3760/cma.j.cn341190-20240508-00526
- VernacularTitle:益生菌联合奥美拉唑治疗儿童急性胃肠炎疗效分析
- Author:
Yingjuan WANG
1
;
Fan YU
Author Information
1. 榆林市第一医院儿科，榆林 719000
- Publication Type:Journal Article
- Keywords:
Gastroenteritis;
Signs and symptoms;
T-lymphocytes;
Immunity;
C-reactive protein;
Interleukin-6;
Drug-related side effects and adverse reactions;
Child;
Omepr
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(10):1492-1497
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of probiotics combined with omeprazole in the treatment of acute gastroenteritis in children.Methods:This study used a prospective design. A total of 110 children with acute gastroenteritis admitted to The First Hospital of Yulin from January to December 2023 were selected for this study. The children were divided into two groups: a control group and an observation group ( n = 55 per group) using a random numbering method. The control group received omeprazole enteric-coated capsules in addition to conventional treatment, while the observation group was treated with butyric acid-producing bifidobacterium and omeprazole enteric-coated capsules. The treatment course for both groups lasted 2 weeks. Clinical symptom scores were compared between the two groups before and after treatment. Additionally, the time to relief of major symptoms, the proportions of T cell subpopulations, changes in serum inflammatory markers, and the incidence of adverse reactions were also compared between the two groups. Results:After treatment, the scores of vomiting, loss of appetite, and diarrhea in the observation group were (1.04 ± 0.14), (0.84 ± 0.09), and (1.55 ± 0.17), respectively, all of which were significantly lower than those in the control group [(1.67 ± 0.18), (1.05 ± 0.12), (2.31 ± 0.25); t = 20.49, 10.38, 18.64, all P<0.001]. The time to relief from vomiting, fever, and diarrhea in the observation group were (1.53 ± 0.52) days, (1.39 ± 0.32) days, and (1.67 ± 0.42) days, which were significantly shorter than those in the control group [(2.88 ± 0.82) days, (2.59 ± 0.31) days, (2.69 ± 0.71) days; t = 10.31, 19.98, 9.17, all P<0.001]. The proportions of CD 3+, CD 4+, and CD 8+ T cells in the observation group were (69.74 ± 7.67)%, (45.32 ± 6.80)%, and (27.61 ± 3.31)%, respectively. They were (62.48 ± 9.37)%, (38.66 ± 5.80)%, and (33.42 ± 4.01)% respectively in the control group. There were significant differences in the proportions of CD 3+, CD 4+, and CD 8+ T cells between the two groups ( t = -4.45, -5.53, 8.29, all P<0.001). The levels of high-sensitivity C-reactive protein, procalcitonin, and interleukin-6 in the observation group were (4.22 ± 0.51) mg/L, (2.55 ± 0.38) ng/L, and (10.25 ± 1.44) ng/L, respectively, all of which were significantly lower than those in the control group [(7.68 ± 1.08) mg/L, (4.78 ± 0.57) ng/L, (18.53 ± 2.22) ng/L; t = 21.48, 24.14, 23.21, all P<0.001]. The level of interleukin-2 in the observation group was significantly higher than that in the control group [(69.74 ± 7.67) pg/L vs. (56.87 ± 8.53) pg/L; t = -8.32, P<0.001]. There was no significant difference in the incidence of adverse reactions between the observation and control groups [7.27% (4/55) vs. 3.64% (2/55); χ2 = 0.18, P>0.05). Conclusions:The combination of probiotics and omeprazole can effectively improve the clinical manifestations of acute gastroenteritis in children, accelerate symptom recovery, enhance immune function, and demonstrate good safety.
